Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM)

BJU International

Volumn 110, Issue 7, 2012, Pages 973-979

  Russo, Andrea L ^a   Chen, Ming Hui ^b   Aizer, Ayal A ^a   Hattangadi, Jona A ^a   D'Amico, Anthony V ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

age related risk; mortality; neoplasm grading; prostatic neoplasms; SEER programme

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER MORTALITY; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR; BLOOD; CAUSE OF DEATH; METABOLISM; MIDDLE AGED; MORTALITY; ONSET AGE; PATHOLOGY; PROSTATE TUMOR; REGRESSION ANALYSIS;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; CAUSE OF DEATH; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84871675005     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11470.x     Document Type: Article

References (31)

1. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-23
2. The American Cancer Society. Cancer Facts & Figures 2010. Available at: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-026238.pdf. Accessed July 2012
3. National Institutes of Health State of the Science Conference Statement. Role of Active Surveillance in the Management of Men with Localized Prostate Cancer, 7 December, 2011. Available at: http://consensus.nih.gov/2011/docs/ prostate/ASPC-Program-and-Abstract-Book.pdf. Accessed July 2012
4. Thompson IM, Ankerst DP, Chi C, et al,. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-34
5. Berry SJ, Coffey DS, Walsh PC, Ewing LL,. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-9
6. Fleshner NE, O'Sullivan M, Fair WR,. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol 1997; 158: 505-9
7. Chang JJ, Shinohara K, Bhargava V, Presti JC Jr,. Prospective evaluation of lateral biopsies of the peripheral zone for prostate cancer detection. J Urol 1998; 160: 2111-4
8. SEER. Surveillance Epidemiology, and End Results (SEER) Program SEER Stat Database: incidence-SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases. 2011. Nov 2010 Sub (1973-2008 varying)-Linked To County Attributes-Total U.S., 1969-2009 Counties. edn National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch., Released April 2011 (updated 10/28/2011), based on the November 2010 submission
9. Hankey BF, Ries LA, Edwards BK,. The Surveillance, Epidemiology, and End Results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999; 8: 1117-21
10. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Prostate Cancer 2011; V4: 6. NCCN
11. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL,. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst 2001; 93: 1822-3
12. German RR, Fink AK, Heron M, et al,. The accuracy of cancer mortality statistics based on death certificates in the united states. Cancer Epidemiol 2011; 35: 126-31
13. Agresti A,. Categorical Data Analysis, 2nd edn. New York: John Wiley & Sons, 2002
14. Hollander M, Wolfe DA,. Nonparametric Statistical Methods, 2nd edn. New York: John Wiley & Sons, 1999
15. Fine JP, Gray RJ,. A proportional hazards model for the sub distribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509
16. Klein JP, Moeschberger M, eds. Survival Analysis: Techniques for Censored and Truncated Data (Statistics for Biology and Health). New York: Springer, 1997: 96-100, 229-68
17. Gray RJ,. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat 1988; 16: 1141-54
18. Hoeks CM, Schouten MG, Bomers JG, et al,. Three-Tesla Magnetic Resonance-Guided Prostate Biopsy in Men With Increased Prostate-Specific Antigen and Repeated, Negative, Random, Systematic, Transrectal Ultrasound Biopsies: detection of Clinically Significant Prostate Cancers. Eur Urol 2012; [Epub ahead of print]. DOI:10.1016/j.eururo.2012.01.047
19. Suardi N, Gallina A, Capitanio U, et al,. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. Cancer 2011; 118: 973-80
20. Shah JB, McKiernan JM, Elkin EP, Carroll PR, Meng MV,. Prostate biopsy patterns in the CaPSURE database: evolution with time and impact on outcome after prostatectomy. J Urol 2008; 179: 136-40
21. Hoeks CM, Barentsz JO, Hambrock T, et al,. Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 2011; 261: 46-66
22. Salagierski M, Schalken JA,. Molecular Diagnosis of Prostate Cancer: PCA3 and TMPRSS2:ERG Gene Fusion. J Urol 2012; 187: 795-801
23. Rastinehad AR, Baccala AA Jr, Chung PH, et al,. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol 2011; 185: 815-20
24. Haffner J, Lemaitre L, Puech P, et al,. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int 2011; 108: E171-8
25. Hambrock T, Somford DM, Hoeks C, et al,. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol 2009; 183: 520-7
26. Hambrock T, Somford DM, Huisman HJ, et al,. Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 2011; 259: 453-61
27. Lin DW, Newcomb LF, Brown EC, et al,. Urinary TMPRSS2: use of ERG and PCA3 to predict tumor volume and Gleason grade in an active surveillance cohort-Results from the Canary/EDRN Prostate Active Surveillance Study. 2012 Genitourinary Cancers Symposium 2012; San Francisco, CA, 2012. J Clin Oncol 2012; 30 (Suppl. 5): abstract 2
28. Nguyen PL, Chen MH, Renshaw AA, Sussman B, D'Amico AV,. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology 2007; 70: 288-93
29. Trpkov K, Zhang J, Chan M, Eigl BJ, Yilmaz A,. Prostate cancer with tertiary Gleason pattern 5 in prostate needle biopsy: clinicopathologic findings and disease progression. Am J Surg Pathol 2009; 33: 233-40
30. Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA,. The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81: e135-42
31. Beard C, Schultz D, Loffredo M, et al,. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66: 403-7